R
Robert C. Shamberger
Researcher at Boston Children's Hospital
Publications - 234
Citations - 11467
Robert C. Shamberger is an academic researcher from Boston Children's Hospital. The author has contributed to research in topics: Wilms' tumor & Pectus excavatum. The author has an hindex of 58, co-authored 227 publications receiving 10345 citations. Previous affiliations of Robert C. Shamberger include Maine Medical Center & Children's Memorial Hospital.
Papers
More filters
Journal ArticleDOI
Loss of Heterozygosity for Chromosomes 1p and 16q Is an Adverse Prognostic Factor in Favorable-Histology Wilms Tumor: A Report From the National Wilms Tumor Study Group
Paul E. Grundy,Norman E. Breslow,Sierra M. Li,Elizabeth Penman,J. Bruce Beckwith,Michael L. Ritchey,Robert C. Shamberger,Gerald M. Haase,Giulio J. D'Angio,Milton Donaldson,Max J. Coppes,Marcio H. Malogolowkin,Patricia Shearer,Patrick R.M. Thomas,Roger M. Macklis,Gail E. Tomlinson,Vicki Huff,Daniel M. Green +17 more
TL;DR: Tumor-specific LOH for both chromosomes 1p and 16q identifies a subset of FH Wilms tumor patients who have a significantly increased risk of relapse and death.
Journal ArticleDOI
Dose-intensified compared with standard chemotherapy for nonmetastatic ewing sarcoma family of tumors: A children's oncology group study
Linda Granowetter,Richard B. Womer,Meenakshi Devidas,Mark Krailo,Chenguang Wang,Mark Bernstein,Neyssa Marina,Patrick J. Leavey,Mark C. Gebhardt,John H. Healey,Robert C. Shamberger,Allen M. Goorin,James S. Miser,James O. Meyer,Carola A.S. Arndt,Scott L. Sailer,Karen J. Marcus,Elizabeth J. Perlman,Paul W. Dickman,Holcombe E. Grier +19 more
TL;DR: Dose escalation of alkylating agents as tested in this trial did not improve the outcome for patients with nonmetastatic ESFT of bone or soft tissue.
Journal ArticleDOI
Treatment of Anaplastic Histology Wilms' Tumor: Results From the Fifth National Wilms' Tumor Study
Jeffrey S. Dome,Cecilia A. Cotton,Elizabeth J. Perlman,Norman E. Breslow,John A. Kalapurakal,Michael L. Ritchey,Paul E. Grundy,Marcio H. Malogolowkin,J. Bruce Beckwith,Robert C. Shamberger,Gerald M. Haase,Max J. Coppes,Peter F. Coccia,Morris Kletzel,Robert M. Weetman,Milton Donaldson,Roger M. Macklis,Daniel M. Green +17 more
TL;DR: The prognosis for patients with stage I AH is worse than that for patientsWith stage I FH, especially those with stage III to V disease, and novel treatment strategies are needed to improve outcomes.
Journal ArticleDOI
Surgery-related factors and local recurrence of Wilms tumor in National Wilms Tumor Study 4.
Robert C. Shamberger,Katherine A. Guthrie,Michael L. Ritchey,Gerald M. Haase,Janice R. Takashima,J. Beckwith,Giulio J. D'Angio,Daniel M. Green,Norman E. Breslow +8 more
TL;DR: This study has demonstrated that surgical rupture of the tumor must be prevented by the surgeon, because spills produce an increased risk of local relapse.
Journal ArticleDOI
Outcome after Reduced Chemotherapy for Intermediate-Risk Neuroblastoma
David L. Baker,Mary Lou Schmidt,Susan L. Cohn,John M. Maris,Wendy B. London,Allen Buxton,Daniel O. Stram,Robert P. Castleberry,Hiroyuki Shimada,Anthony D. Sandler,Robert C. Shamberger,A. Thomas Look,C. Patrick Reynolds,Robert C. Seeger,Katherine K. Matthay +14 more
TL;DR: A very high rate of survival among patients with intermediate-risk neuroblastoma was achieved with a biologically based treatment assignment involving a substantially reduced duration of chemotherapy and reduced doses of chemotherapeutic agents as compared with the regimens used in earlier trials.